The purpose of this study is to evaluate the safety and effectiveness of the Elevate System for patients needing non-emergent percutaneous coronary intervention (PCI).

The Elevate System is an investigational heart pump device, which means it has not been approved by the U.S. Food and Drug Administration (FDA). It is being compared with an already approved heart pump device called the Impella System. The Impella System is approved for patients having HR-PCI.

The purpose of this study is to evaluate the safety and efficacy of percutaneous endovascular catheter-facilitated intramyocardial delivery of XC001 in treating refractory angina compared to standard treatment.

The purpose of this study is to see if an experimental device, called the Shockwave Medical Inc. Reducer System (Reducer) is safe and useful in treating refractory angina compared to standard treatment.

Experimental means that the device is not approved by the U.S. Food and Drug Administration (FDA).

 The primary objective of the study is to evaluate the effectiveness and safety of brelovitug (BJT-778) as a long-term treatment in participants with chronic hepatitis delta virus (HDV) infection, the virus responsible for chronic hepatitis D (CHD).

BJT-778 is an investigational study drug, which  means that it is not an approved treatment for HDV infection by the U.S. Food and Drug Administration (FDA)    

We’d like to hear about the experience when getting cancer care among adults with colorectal, pancreatic, esophageal, or gastric cancer, who live in underserved communities in New York City.

This study is to better understand which challenges people face when obtaining care. Our goal is to identify opportunities to improve the process of obtaining care after being diagnosed with cancer.

This is an observational study. This study is for men and women who will undergo endoscopic resection of a ≥ 10 mm adenomatous duodenal polyp.
   
The purpose of this registry study is is to understand how to improve polyp resection of large polyps in the small intestine, and how to make it as effective and as safe as possible.
   

The purpose of this study is to test if an investigational study drug, pegozafermin, is safe and effective in treating patients with compensated cirrhosis due to MASH metabolic dysfunction-associated steatohepatitis (MASH). 
   

Dravet syndrome is a severe form of epilepsy (a brain disorder that causes seizures). There are several types of therapies available to help reduce the number of seizures. However, even with treatment using current anti-seizure therapies, the number of seizures may not be reduced enough, and seizures may still happen. 

This clinical trial is for adults who have been diagnosed with advanced stage cancer. 
   
The purpose of this study is to determine if the investigational drug GIM-531 is safe and whether it can help a participant’s immune system attack and kill cancer cells, or if the addition of GIM-531 to their anti-PD-1 therapy can help this drug work better to kill cancer cells.
   

This clinical trial is designed for men and women with Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 or high risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) who are ineligible for treatment with a Janus kinase (JAK) inhibitor.

The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug Reparixin to treat myelofibrosis. Investigational means Reparixin is not approved by the U.S. Food and Drug Administration (FDA).